Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Reply.
Stüssi-Helbling M, Arrigo M, Huber LC. Stüssi-Helbling M, et al. Among authors: huber lc. Am J Med. 2020 Feb;133(2):e64. doi: 10.1016/j.amjmed.2019.09.004. Am J Med. 2020. PMID: 31954478 No abstract available.
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.
Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, Raeber ME, Adamo S, Weigang S, Emmenegger M, Hasler S, Bosshard PP, De Cecco E, Bächli E, Rudiger A, Stüssi-Helbling M, Huber LC, Zinkernagel AS, Schaer DJ, Aguzzi A, Kochs G, Held U, Probst-Müller E, Rampini SK, Boyman O. Cervia C, et al. Among authors: huber lc. J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9. doi: 10.1016/j.jaci.2020.10.040. Epub 2020 Nov 20. J Allergy Clin Immunol. 2021. PMID: 33221383 Free PMC article.
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
Urwyler P, Charitos P, Moser S, Heijnen IAFM, Trendelenburg M, Thoma R, Sumer J, Camacho-Ortiz A, Bacci MR, Huber LC, Stüssi-Helbling M, Albrich WC, Sendi P, Osthoff M. Urwyler P, et al. Among authors: huber lc. Trials. 2021 Jan 4;22(1):1. doi: 10.1186/s13063-020-04976-x. Trials. 2021. PMID: 33397449 Free PMC article.
A distinct innate immune signature marks progression from mild to severe COVID-19.
Chevrier S, Zurbuchen Y, Cervia C, Adamo S, Raeber ME, de Souza N, Sivapatham S, Jacobs A, Bachli E, Rudiger A, Stüssi-Helbling M, Huber LC, Schaer DJ, Nilsson J, Boyman O, Bodenmiller B. Chevrier S, et al. Among authors: huber lc. Cell Rep Med. 2020 Dec 26;2(1):100166. doi: 10.1016/j.xcrm.2020.100166. eCollection 2021 Jan 19. Cell Rep Med. 2020. PMID: 33521697 Free PMC article.
Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19.
Adamo S, Chevrier S, Cervia C, Zurbuchen Y, Raeber ME, Yang L, Sivapatham S, Jacobs A, Baechli E, Rudiger A, Stüssi-Helbling M, Huber LC, Schaer DJ, Bodenmiller B, Boyman O, Nilsson J. Adamo S, et al. Among authors: huber lc. Allergy. 2021 Sep;76(9):2866-2881. doi: 10.1111/all.14866. Epub 2021 Jun 30. Allergy. 2021. PMID: 33884644 Free PMC article.
Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome.
Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, Adamo S, Raeber ME, Bächli E, Rudiger A, Stüssi-Helbling M, Huber LC, Nilsson J, Held U, Puhan MA, Boyman O. Cervia C, et al. Among authors: huber lc. Nat Commun. 2022 Jan 25;13(1):446. doi: 10.1038/s41467-021-27797-1. Nat Commun. 2022. PMID: 35078982 Free PMC article.
138 results